The effect of glimepiride on pancreatic β-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus

Hormone and Metabolic Research

Volumn 28, Issue 9, 1996, Pages 445-450

  Clark, H E ^a   Matthews, D R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

C peptide; Cross over trial; Double blind; Euglycaemic glucose clamp; Glibenclamide; Glomepiride; Hyperglycaemic glucose clamp; Hyperinsulinaemic; Insulin; Non insulin dependent diabetes; Placebo controlled; Sulfonylurea

Indexed keywords

C PEPTIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; INSULIN; PLACEBO; SULFONYLUREA DERIVATIVE;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029845670     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979835     Document Type: Conference Paper

References (17)

1. Beck-Nielsen, H., O. Nother Nielsen, P. H. Anderson, O. Pederson, O. Schmitz: In vivo action of glibenclamide. Diabetologia 29: 515A (1986)
2. Draeger, E.: Clinical profile of glimepiride. Diabetes Res. Clin. Pract. 28 (Suppl.): S139-S146 (1995)
3. Ferner, R., H. A. W. Neil: Sulphonylureas and hypoglycaemia. BMJ 296: 949-950 (1988)
4. Harrower, A. D.: Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J. Diabetes Complications 8: 201-203 (1994)
5. Holman, R. R., R. C. Turner: Diabetes: the quest for basal normoglycaemia. Lancet 1: 469-474 (1977)
6. Jackson, E. J., R. Bressler: Clinical pharmacology of sulphonylurea hypoglycaemic agents. Drugs 22: 211-245 (1981)
7. Kolterman, O. G., J. M. Olefsky: The impact of sulphonylurea tretment upon the mechanisms responsible for the insulin resistance in Type II diabetes. Diabetes Care 7: 81-88 (1984)
8. Kramer, W., G. Muller, F. Girbig, U. Gutjahr, S. Kowalewski, D. Hartz, H. D. Summ: The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels. Diabetes Res. Clin. Pract. 28 (Suppl.): S67-S80 (1985)
9. Matthews, D. R., J. P. Hosker: Unbiased and flexible iterative computer program to achieve glucose clamping. Diabetes-Care 12: 156-159 (1989)
10. Melander, A.: Clinical pharmacology of sulphonylureas. Metabolism 36: 12-16 (1987)
11. Pontiroli, A. E., A. Caldera, G. Pozza: Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management. Diabetes Metab. Rev. 10: 31-43 (1994)
12. Robertson, D. A., P. D. Home: Problems and pitfalls of sulphonylurea therapy in older patients. Drugs Aging 3: 510-524 (1993)
13. Shapiro, E. T., H. Tillil, M. A. Miller, G. H. Frank, J. A. Galloway: Insulin secretion and clearance: comparison after oral and intravenous glucose. Diabetes 36: 1365-1371 (1987)
14. Siconfi-Baez, L., H. E. Lebovitz: Chracteristics of a specific plasma membrane sulphonylurea receptor. Diabetes 34: 228-232 (1985)
15. Simonson, D. C., E. Ferrannini, S. Bevilacqua, D. Smith, E. Barrett: Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes 33: 838-845 (1984)
16. Tsumura, K., E. Draeger: Clinical evaluation of glimepiride (HOE 490) in NIDDM, including a double blind comparative study versus gliclazide. Diabetes Res. Clin. Pract. 28: S147-S149 (1995)
17. Ward, G., L. C. Harrison, J. Proietto, P. Aitken, A. Nankervis: Gliclazide therapy is associated with potentiation of postbinding insulin action in obese, non-insulin-dependent diabetic subjects. Diabetes 34: 241-245 (1985)